Recent Articles By The Author
Assuming that enough of you are either long NVDA, or at least have an interest in the name, let's take a look under the hood, and make a more determined decision here.
The risk is that the chief design officer's departure will cause technical issues in Apple's chart.
The risk/reward ratio doesn't look good for retail investors.
The G-20 Summit in Japan could hold more intrigue than just the planned meeting between President Trump and Xi.
The trouble for me, as an investor, is that this business remains in decline until it is not in decline.
Key to a China trade deal will be that both sides come away from the G-20 meeting with the feeling that progress has been made, and that the schedule of tariffs has not been expanded.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
Plus, a look at Ulta Beauty and a possible options play in the retailer.